Section II 
DR. TOWNSEND: I do not think we really know the answer right now to 
the question of nicotine distribution between the gas and particulate phase. 
1 do think we have confidence that the FTC method can provide useful data 
for Eclipse. Certainly the FTC method will have to be accommodated for 
that product in much the same way that the FTC considered accommodating 
the method for Barclay and the use of different holders. That proposal 
was certainly up for discussion. The FTC method as it stands with some 
modification, particularly for the fact that Eclipse does not burn down, 
can provide useful data for that. 
DR. FREEMAN: Dr. Henningfield? 
DR. HENNINGFIELD: In dealing with the smokeless tobacco issue, which 
has no labeling, and 1 think that is a problem, it struck me yesterday that I 
am not sure what is worse, having no labeling or having labeling that might 
be misleading to consumers about relative risks. In trying to deal with the 
relative risk issue yesterday, you spent a lot of time talking about your 
technologies that address health concerns and implying that there was some 
health benefit, and I would like to know what your estimate is as to the 
number of cancer deaths, for example, caused by standard cigarettes and 
how many lives, if any, would be saved if people were using cigarettes with 
these advanced technologies of filtration and so forth that you were talking 
about yesterday? In other words, how many people die of cancer in your 
estimation from the higher yield cigarettes, and how many fewer, if any, 
would die from the lower yield cigarettes? 
DR. TOWNSEND: I think what you did was completely mischaracterize what 
I said yesterday. What 1 said was that the Surgeon General and the public 
health community called for the reduction in tar and nicotine yields from 
cigarettes, and I said that the industry and R.J. Reynolds responded to that 
consumer demand through major design changes to the product, and we 
successfully reduced the tar and nicotine yields from the very high 30's, 
as a sales-weighted average, down to currently about 12 mg. 
DR. FREEMAN: To follow up on the question, do you think that fewer 
people die based on the changes that you have made? 
DR. TOWNSEND: 1 am not an epidemiologist. The Surgeon General in 1981, 
in his report, did say that reduced-tar products pose a reduced health risk. 
DR. HENNINGFIELD: I would like to follow this though because the words 
"light" and things like that are only used with foods when there is a health 
benefit. Your industry is using those terms relating them to FTC yields, and 
I would like to know what your estimate of the health benefit is. To know 
that, we have to know what your estimate of the death rates are with the 
different products. 
DR. TOWNSEND: I just said that I was not an epidemiologist. I happen to 
be a chemist. I do know what the Surgeon General and epidemiologists have 
said. Many smokers have heard the same thing. 
I 
195 
